Q1 Earnings Estimate for Cencora Issued By Leerink Partnrs

Cencora, Inc. (NYSE:CORFree Report) – Leerink Partnrs boosted their Q1 2025 earnings per share estimates for Cencora in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings of $3.45 per share for the quarter, up from their prior forecast of $3.43. The consensus estimate for Cencora’s current full-year earnings is $14.86 per share. Leerink Partnrs also issued estimates for Cencora’s Q2 2025 earnings at $4.12 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.99 EPS, FY2027 earnings at $18.91 EPS and FY2028 earnings at $20.72 EPS.

A number of other research analysts have also recently commented on the stock. Robert W. Baird upped their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday. Wells Fargo & Company upped their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a report on Thursday, August 1st. Barclays increased their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday. Leerink Partners cut their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Finally, StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $271.20.

Check Out Our Latest Research Report on COR

Cencora Trading Up 0.3 %

Shares of COR stock opened at $248.41 on Friday. Cencora has a fifty-two week low of $191.11 and a fifty-two week high of $251.00. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.55 and a current ratio of 0.88. The stock’s fifty day moving average is $231.95 and its two-hundred day moving average is $230.79. The firm has a market capitalization of $48.95 billion, a P/E ratio of 33.08, a PEG ratio of 1.55 and a beta of 0.44.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be paid a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Friday, November 15th. Cencora’s dividend payout ratio (DPR) is 27.16%.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the transaction, the chairman now owns 285,088 shares in the company, valued at approximately $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.80% of the company’s stock.

Hedge Funds Weigh In On Cencora

Large investors have recently made changes to their positions in the stock. Lake Street Advisors Group LLC boosted its position in Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after purchasing an additional 43 shares in the last quarter. Financial Advocates Investment Management grew its stake in Cencora by 4.7% in the 2nd quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after acquiring an additional 44 shares during the last quarter. Venturi Wealth Management LLC increased its holdings in Cencora by 1.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock valued at $1,001,000 after acquiring an additional 46 shares in the last quarter. Prime Capital Investment Advisors LLC raised its position in Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after acquiring an additional 46 shares during the last quarter. Finally, Checchi Capital Advisers LLC lifted its holdings in shares of Cencora by 2.2% in the second quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock valued at $499,000 after purchasing an additional 48 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

(Get Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Further Reading

Earnings History and Estimates for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.